Abstract:The recent development of prime editing (PE) genome engineering technologies has the potential to significantly simplify the generation of human pluripotent stem cell (hPSC)-based disease models. PE is a multicomponent editing system that uses a Cas9-nickase fused to a reverse transcriptase (nCas9-RT) and an extended PE guide RNA (pegRNA). Once reverse transcribed, the pegRNA extension functions as a repair template to introduce precise designer mutations at the target site. Here, we systematically compared the editing efficiencies of PE to conventional gene editing methods in hPSCs. This analysis revealed that PE is overall more efficient and precise than homology-directed repair of site-specific nuclease-induced double-strand breaks. Specifically, PE is more effective in generating heterozygous editing events to create autosomal dominant disease-associated mutations. By stably integrating the nCas9-RT into hPSCs we achieved editing efficiencies equal to those reported for cancer cells, suggesting that the expression of the PE components, rather than cell-intrinsic features, limit PE in hPSCs. To improve the efficiency of PE in hPSCs, we optimized the delivery modalities for the PE components. Delivery of the nCas9-RT as mRNA combined with synthetically generated, chemically-modified pegRNAs and nicking guide RNAs improved editing efficiencies up to 13-fold compared with transfecting the PE components as plasmids or ribonucleoprotein particles. Finally, we demonstrated that this mRNA-based delivery approach can be used repeatedly to yield editing efficiencies exceeding 60% and to correct or introduce familial mutations causing Parkinson's disease in hPSCs.

Safe scarless cassette-free selection of genome-edited human pluripotent stem cells using temporary drug resistance

Genome Editing of Isogenic Human Induced Pluripotent Stem Cells Recapitulates Long QT Phenotype for Drug Testing.

A Tet-Inducible CRISPR Platform for High-Fidelity Editing of Human Pluripotent Stem Cells

A Cell-Based Optimised Approach for Rapid and Efficient Gene Editing of Human Pluripotent Stem Cells

Using Gene Editing to Establish a Safeguard System for Pluripotent Stem-Cell-Based Therapies.

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Highly efficient genome editing via CRISPR–Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression

Small Molecules Promote CRISPR-Cpf1-mediated Genome Editing in Human Pluripotent Stem Cells

Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells

Development of an efficient single-cell cloning and expansion strategy for genome edited induced pluripotent stem cells

Semi-automated optimized method to isolate CRISPR/Cas9 edited human pluripotent stem cell clones

Highly efficient generation of isogenic pluripotent stem cell models using prime editing

Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9

An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells

Highly Efficient Genome Editing of Human Hematopoietic Stem Cells Via a Nano-Silicon-blade Delivery Approach.

Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

CRISPR-Cas12a for Highly Efficient and Marker-Free Targeted Integration in Human Pluripotent Stem Cells

Fast-Track and Integration-Free Method of Genome Editing by CRISPR/Cas9 in Murine Pluripotent Stem Cells

High-Level Precise Knockin of Ipscs by Simultaneous Reprogramming and Genome Editing of Human Peripheral Blood Mononuclear Cells.

Enhancing genome editing in hPSCs through dual inhibition of DNA damage response and repair pathways